What the review asked
Alevizou and colleagues, publishing in Odontology on 20 July 2026, asked whether autologous platelet derivatives improve regenerative endodontic procedures in immature necrotic permanent teeth, compared with the traditional blood clot scaffold. The question matters because the blood clot is the free, default scaffold in these procedures, and platelet concentrates are widely promoted as an upgrade. The review followed PRISMA guidelines under a protocol registered in PROSPERO (CRD420250492243, registered April 2025), searched PubMed, Web of Science and Scopus up to April 2025, used two independent reviewers, assessed risk of bias with the SYRCLE tool, and pooled results with random-effects meta-analysis.
What the evidence base contains
The search identified 836 records; 10 studies met the inclusion criteria, covering 45 animals and 393 teeth. Included studies assessed regenerative endodontic procedures in immature permanent necrotic teeth with open apices and compared at least one platelet derivative group against a blood clot control. Follow-up periods varied across 1, 2, 3 and 6 months. This is a thin base for a meta-analysis, and the authors treat histological outcomes descriptively because of substantial data heterogeneity.
What the pooled analysis found
Across all time points, the pooled analyses showed no statistically significant differences between platelet derivative and blood clot groups for clinical and radiographical outcomes. Histologically, both scaffolds primarily promoted the formation of mineralized tissue resembling cementum or bone, while true pulp or dentin regeneration remained limited. The authors’ conclusion is blunt: the currently available preclinical evidence does not show clear superiority of either scaffold, and further standardized animal studies with longer follow-up and detailed tissue characterization are required.
What it means for the programme
This bears directly on pulp-dentin-repair, the tier 3 programme where human data exists (the autologous pulp stem cell trial recorded in our /ledger/ on 22 August 2018). Two readings follow. First, scaffold enthusiasm should be discounted: a pooled animal synthesis finds the marketed upgrade indistinguishable from the default. Second, the histology finding reinforces this site’s standing caveat about regenerative endodontics: the tissue that fills the canal is frequently bone-like or cementum-like, not regenerated pulp. On the tier ladder at /method/ this is a T2 synthesis, animal data only, so it moves no tier, but it disciplines what the animal evidence can be claimed to support.
Where we differ from the coverage
Platelet concentrates are routinely described in dental coverage as regenerating pulp tissue. This synthesis, limited to animal models and registered in advance, finds no measurable advantage over a blood clot and reports that the tissue formed mostly resembles cementum or bone. That is the honest boundary of the preclinical record.
Provenance: every claim above traces to the paper’s published abstract, per our method at /method/.